These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20567009)

  • 1. Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
    Chlebowski RT; Chen Z; Cauley JA; Anderson G; Rodabough RJ; McTiernan A; Lane DS; Manson JE; Snetselaar L; Yasmeen S; O'Sullivan MJ; Safford M; Hendrix SL; Wallace RB
    J Clin Oncol; 2010 Aug; 28(22):3582-90. PubMed ID: 20567009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
    Hue TF; Cummings SR; Cauley JA; Bauer DC; Ensrud KE; Barrett-Connor E; Black DM
    JAMA Intern Med; 2014 Oct; 174(10):1550-7. PubMed ID: 25111880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative.
    Passarelli MN; Newcomb PA; LaCroix AZ; Lane DS; Ho GY; Chlebowski RT
    J Bone Miner Res; 2013 Sep; 28(9):2043-8. PubMed ID: 23519920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
    Pazianas M; Abrahamsen B; Eiken PA; Eastell R; Russell RG
    Osteoporos Int; 2012 Nov; 23(11):2693-701. PubMed ID: 22392160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
    Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonate use and lung cancer incidence among postmenopausal women.
    Tao MH; Chen S; Freudenheim JL; Cauley JA; Johnson KC; Mai X; Sarto GE; Wakelee H; Boffetta P; Wactawski-Wende J
    Ann Oncol; 2018 Jun; 29(6):1476-1485. PubMed ID: 29617712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
    Monsees GM; Malone KE; Tang MT; Newcomb PA; Li CI
    J Natl Cancer Inst; 2011 Dec; 103(23):1752-60. PubMed ID: 22021667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
    J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.
    Ou YJ; Chiu HF; Wong YH; Yang CC; Yang YH
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1286-1295. PubMed ID: 28857419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.